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INTRODUCTION
Psoriasis  is  a  chronic  inflammatory  skin condition of  unknown aetiology 
which affects approximately 1-3% of the worlds  population[1]. Clinically psoriasis 
manifests as  erythematous  plaques covered with silvery scales. It is characterized 
by  hyperproliferation  and  abnormal  differentiation  of  epidermal   kertinocytes, 
lymphocyte infiltration consisting mostly of T lymphocytes and various endothelial 
vascular changes in the dermis such as angiogenesis,dilation and high endothelial 
venule formation. [2]Both genetic and environmental factors contribute to aetiology. 
Psoriasis  is  usually  a  life  long disease  with  varying periods  of  remissions  and 
exacerbations. The therapeutic options are wide ranging from topical to systemic 
agents and  phototherapy. The goals of therapy should be to gain initial and rapid 
control of the disease process, achieve a longer duration of remission, provide a 
better quality of life by reducing the severity and minimizing the side effects.
Phototherapy is the use of non- ionising  radiation as a treatment modality. 
In the past three decades , phototherapy has greatly influenced treatment concepts 
in  dermatology.  Photochemotherapy  (PUVA)  consists  of  absorption  of  non-
ionizing radiation by an exogenous molecule. This substance is usually psoralen 
that is derived from the plant source ammi majus, psoralea corylofolia.
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UV radiation has been used in the management of skin diseases such as psoriasis 
and atopic dermatitis. The prototypic skin disease showing a favourable response 
to UVB phototherapy is psoriasis.  UVB Phototherapy are now belived to act by 
immunomodulatory effects on human skin and suppression of accelerated DNA 
synthesis in psoriatic epidermal cells and this is important for of UV phototherapy. 
Narrow-band  UVB(NbUVB; 311-313nm) has proved as effective as PUVA with 
minimal long term side effects such as carcinogenicity. 
Since photochemotherapy entails the use of psoralen. It is associated with 
more side effects and cannot be administered to children. However, Narrow – band 
UVB   is  effective  without  the  use  of  psoralen  and  so  is  gradually  replacing 
photochemotherapy. There are certain cases which do not respond adequately to 
both PUVA and  NbUVB. This study is undertaken to determine whether addition 
of psoralen makes Nb UVB more effective than NbUVB without psoralen.
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Aims and Objectives
To compare  Narrowband  UVB and  Narrowband  P-UVB in  treatment  of 
Chronic plaque type Psoriasis.
3
REVIEW OF LITRATURE                      
      PSORIASIS  
History
Psoriasis is one of the longest known illnesses of humans . Although the name 
psoriasis was not introduced for many years the actual condition of psoriasis was 
first talked of by the Greek physician ,Hippocrates who lived between 460 and 377 
BC.Some  scholars  believe  psoriasis  to  have  been  included  among  the  skin 
conditions  called  tzaraat  in  the  bible.The  biblical  term  ‘lepra’  was  applied  to 
various  cutaneous  disorders  including  psoriasis,  vitiligo,  eczema,  boils  and 
alopecia areata.[3]
 The Roman sage Aureliues  Cornelius Celsus  is  credited with the first  clinical 
description of psoriasis.[4].Galen was the first to use the term Psoriasis and Robert 
Willain in  1808 (1757-1812) recognized psoriasis  as  an independent  disease.[5]. 
Robert Willain identified two categories. Leprosa Graecorum was the term he used 
to describe the condition when the skin had scales.Psora Leprosa described the 
condition  when  it  became  eruptive.In  1841  Ferdinand  Von  Hebra,  a  Viennese 
Dermatologist definitely distinguished the clinical features of psoriasis from that of 
leprosy.
Epidemiological aspects:
Estimates of the occurrence of psoriasis  in different parts of the world vary from 
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0.1 to 3% [6,7].Psoriasis can present at any age and can appear just after birth or in 
old age [8].  There is a bimodal age of onset, the first peak at 15 – 20 years of age 
and a second one at 55 – 60 years.  A North Indian study found that the mean age 
of onset was higher for males than females (37 vs 29 years)  [9].  Possession of 
certain HLA antigens, particularly HLA-Cw6, is associated with an earlier age of 
onset and a positive family history.
A high familial  occurrence of psoriasis (7% - 36%) suggests that genetic 
factors  play  a  role  in  its  etiology  [8,10-13]  Psoriasis  occurs  with  almost  equal 
frequency in males and females[8]
Aetiopathogenesis :
Hypothesis of psoriasis pathogenesis have changed over the decades but its 
etiology still  not  known.  [14].With the availability  of  monoclonal  antibodies  the 
pattern  of  inflammatory  infiltrate  in  the  psoriatic  lesion  was  characterized  and 
evidence accumulated to suggest that psoriasis is a T cell mediated autoimmune 
chronic inflammatory disease.
1. Presence of clonal population of T cells in the dermis (CD4 T cells) and 
epidermis (CD8 T Cells) which may precede epidermal hyperplasia.
2. Prompt response to therapeutic agents specifically targeting T lymphocytes 
eg. Cyclosporine.
5
3. Increased expression of some adhesion molecules that promote leukocyte 
adherence, such as ICAM-1 and E–Selectin.
Regenerate Keratinocyte Differentiation in Psoriasis:
The increased keratinocyte proliferation in psoriasis is believed to be due to 
an increase in the proliferating cell compartment in the basal and suprabasal layer 
(about 10% of basal keratinocytes are cycling in normal skin, while in lesional skin 
this is up to 100%) rather than due to shortened cell cycle time.  The trainst from a 
basal keratinocyte to a desquamated cell takes 4 – 6 weeks in normal skin, but in 
psoriasis  this  occurs  in  only  a  few  days[15]  The  result  of  this  incomplete 
differentiation /  parakeratosis  is  that the stratum corneum barrier is  not formed 
correctly in psoriasis plaques resulting in a defective barrier and the shedding of 
stratum corneum fragments in large sheets of scales / flakes [15]
Genetic Factors :
Patients with psoriasis have an increased frequency of HIA–B13, HLA – 
B17 and HLA–Bw16[16-18]  One of the most susceptible factor is the presence of 
HLA–Cw0602  [19]  The  best  established  locus  is  PSORSI,  which  has  been 
identified in all genetic studies and accounts for 35% - 50% of the genetic liability 
to psoriasis.
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Immunopathogenesis of Psoriasis:
Both innate and acquired immunity contribute in pathogenesis [20]  Psoriasis 
is an immunologically mediated disease caused by activation of T lymphocytes 
that elaborate a Th1 type of immune response.
In  normal  skin,  there  are  a  few  T  cells  in  the  dermis  (but  none  in  the 
epidermis),  a  few myeloid  (CD11C+)  dendritic  cells  (DCs)  in  the  dermis  and 
langerhans cells mainly and relatively uniformly in the epidermis [15]
In  Psoriasis  lesions,  T  cells  and  dendritic  cells  form  dense  dermal 
aggregates, the number of DCs equaling or exceeding that of T cells.  CD4 T cells 
are predominantly present in the upper dermis, CD8 T cells in all layers of the 
epidermis and myeloid DCs in the dermis and lower layers of the epidermis, while 
langerhans cells migrate into the upper spinous layer and neutrophils accumulate in 
small aggregates in the stratum corneum [15]  While these leukocytes can enter the 
skin by transmigration through vessels, the resident leukocytes could also expand 
to create the infiltrate [21]
Possible steps in the pathogenesis of Psoriasis
1. T cell activation by presentation of antigen by the antigen presenting cell in 
the lymph nodes.
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2. T  cell  binding  to  the  endothelium  in  the  vasulature  with  subsequent 
migration into the skin.
3. T cell  reactivation by a  second exposure  to  antigen which occurs in  the 
dermis or epidermis.
4. Production  of  cytokines  by  various  effector  cells  and  development  of 
psoriasis
5. Transition  of  the  autoimmune  process  to  the  joints  and  development  of 
arthritis.
To  generate  a  cutaneous  T-cell  response,  antigen  presenting  cells 
(langerhans cells in the epidermis) take up and process autoantigens and migrate to 
the regional lymphnodes.  There, they come in contact with naive T lymphocytes 
(CD45RA+).  Within an immunologic synapse, molecular interactions result in T-
cell activatioin [22]
According to the putative theory, antigen–presenting cells present processed 
antigen bound to major- histocompatibility – complex (MHC) molecules to the T-
cell receptor (TCR).  MHC Class II molecules present antigen to CD4 + T cells, 
whereas MHC Class  I  molecules present  antigen to CD8+ T cells.   Additional 
signals are transmitted through interactions of co-stimulatory molecules with their 
ligands such as CD2 with CD58, CD28 with either CD80 or CD86, or both.  In 
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addition,  adhesive  interactions  (eg  by  integrins  and  their  immunoglobulin 
superfamily ligands) also stabilize the immunologic synapse and tranmit additional 
signals.   Following the activating signals,  T cells differentiate  into CD45 RO+ 
memory  T  cells  and  express  skin-homing  receptor  cutaneous  lymphocyte  – 
associated antigen (CLA).  Once activated, T cells (CD45RO+ and CLA+) reenter 
the circulation and preferentially extravasate at sites of cutaneous inflammation.  In 
the  skin,  on  encountering  the  respective  antigen,  T  cells  exert  their  effector 
functions, which include the secretion of pro-inflammatory cytokines.  Psorasis is 
characterized by a chronically persisting response in effector  T cells.
Recently, it was estimated that the entire normal skin surface contains twice the 
number  of  T  cells  in  the  circulation  [21,23]  There  was  also  TNF–α  induced 
endogeneous  activation  of  DCs  and  non-lesional  resident  T  cells  in  psoriatic 
patients  [24] These  findings  suggest  that  the apparently  normal  skin  of  psoriatic 
susceptible patients already contains a cellular microenvironment which becomes 
self – perpetuating once the disease process is initiated by bacterial antigens or 
superantigens [25]
An alternative theory is that the innate immune system initiates the psoriatic 
lesion, but in the process, neoantigens, become exposed.  These antigens induce an 
adaptive immune response that maintains the psoriatic lesion[26]  Thus, both the 
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innate  and adaptive  immune  systems trigerred  by environmental  stimuli  and/or 
putative  psoriatic  antigens  could  act  synergistically  to  induce  psoriasis  in  a 
genetically predisposed individual.
Triggering and Modifying Factors :
1. Local Factors – Psoriatic  lesions tend to develop at sites of injury to the 
skin.   The  koebner  phenomenon  refers  to  the  induction  of  lesions  by 
cutaneous trauma[27]
2. Seasonal Variations
Most patients experience worsening of their skin lesions during winter [6,7]
3. Pregnancy
Psoriasis may remit during pregnancy.  This is due to increased IL–10 levels 
in the circulation
4. Emotional Stress
60% of patients describe stress as being a key exacerbator or trigger of their 
disease .
5. Infections 
Upper respiratory tract infections and tonsillitis especially when caused by 
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streptococci  may cause a flare-up of existing psoriasis or may precipitate an 
attack of acute guttate psoriasis  [28-30].  An abnormal group A streptococcal 
and infection may play an important role in the exacerbation of psoriasis [31]
6. Drugs
Many  drugs  can  precipitate  or  exacerbate  psoriasis  particularly  beta  – 
blockers, lithium, anti–malarials, imiquimod, interferons, Non-steroidal anti-
inflammatory drugs and Angiotensin converting enzyme inhibitors[32-43]
7. Sunlight,  Alcohol  and  smoking  are  other  factors  associated  with 
exacerbation of psoriasis.
Clinical Features:
The characteristic clinical presentation of chronic plaque type psoriasis is 
erythematous, well defined, scaly papules and plaques.  It can also present as 
small papules (guttate psoriasis) pustules (pustular psoriasis) and generalized 
erythema and scaling (erythrodermic psoriasis).
The scales are abundant, dry and silvery white or micaceous.  Whiteness is 
due to the presence of air trapped in between the layers of sales.  When these 
scales are scraped off,  the stratum mucosum is exposed and is seen as a 
moist red surface (membrane of bulkeley) through which dilated capillaries 
11
can be seen as red spots.  On further scraping these capillaries at the tips of 
elongated papillae are torn leading to multiple bleeding points.  This is a 
characteristic feature of Auspitz sign.  Psoriasis can be clinically classified 
as follows
1. Chronic plaque psoriasis
2. Guttate psoriasis
3. Pustular psoriasis
4. Exfoliative psoriasis
5. Psoriasis unguis
6. Mucous membrane psoriasis
7. Arthropathic psoriasis
8. Regional variations in psoriasis – Scalp, face, eyes, body, flexures, scrotum, 
napkin area, palms and soles.
Chronic plaque psoriasis is the commonest type, seen in 90% of patients.  The 
extensor surfaces particularly of elbows and knees, lumbosacral area and back 
are commonly involved.
Investigations :
The diagnosis of psoriasis can usually be made on clinical grounds and biopsy 
is occasionally required.  The histopathological features are
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1. Parakeratois
2. Presence of ‘microabcesses of munro’ in the horny layer
3. Absence of a granular layer
4. Regular elongation of rete ridges, their lower portion is thickened showing a 
camel foot like shape.
5. Dilated and tortuous capillaries in the papillae with edema and perivascular 
mononuclear cell infiltration.
6. Thinning of suprapapillary parts of the stratum malphigii  with occasional 
presence of spongiform pustules.
Treatment :
The nature of the disease and its chronicity with periods of remissions and 
exacerbations  should be explained to  the patient.   The topical  and systemic 
agents may give symptomatic relief and may prolong remission.
Topical  treatment  includes  emollients,  tar,  corticosteroids,  anthralin, 
keratolytics, calcipotriene and tazarotene.  Systemic therapies for moderate to 
sever  psoriasis  includes   methotrexate,  acitretin,  cyclosporine  and  biologic 
agents.  
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Topical therapy
Topical corticosteroids
Topical  corticosteroids  remain  the  most  widely  prescribed  treatment  for 
psoriasis worldwide. The more potent agents provide rapid efficacy, cosmetic 
acceptability, and versatility in use. A systematic review has shown that potent 
and  very  potent  topical  steroids  are  more  efficacious  for  psoriasis  than  are 
agents  that  have  mild  and  moderate  potency.  A  major  limitation  in  the 
assessment  of  topical  steroids  is  the  short  duration  of  clinical  trials,  which 
makes  issues  such  as  tachyphylaxis  (loss  of  efficacy  with  ongoing therapy) 
difficult  to  appraise.  Additionally,  local  effects  such  as  skin  atrophy, 
telangiectasia,  striae  distensae,  and  purpura,  and  systemic  effects  such  as 
iatrogenic  Cushing's  syndrome  and  hypothalamic-pituitary-adrenal  axis 
suppression, are seen with extensive treatment; subclinical cutaneous atrophy 
occurs in a substantial proportion of patients receiving these treatments for 4 
weeks  or  longer.  These  side-effects  are  most  likely  with  high  potency 
corticosteroids; guidelines restrict the use of such agents to no more than twice 
a  day  for  up  to  two  consecutive  weeks  (50  g  maximum  per  week)  and 
discourage their use on the face or intertriginous areas. To minimise 
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complications, various innovative regimens are used, such as use at weekends 
only,  combination  with  non-steroidal  agents,  and  transition  to  products  of 
weaker potency when initial clinical response has been obtained. 
Vitamin D derivatives
Since their introduction in the early 1990s, these agents have become first-line 
therapy for plaque psoriasis, either as monotherapy or in combination. Initial 
clinical responses with these preparations are inevitably slower than with higher 
potency corticosteroid agents, but their longer-term safety profile makes them 
valuable  for  maintenance  therapy.  Currently,  three  topical  vitamin  D 
compounds are available: calcitriol (the active metabolite of vitamin D) and its 
synthetic analogues, tacalcitol and calcipotriol. These derivatives, available as 
creams, ointments, or solutions, are generally applied once or twice daily. A 
proposed benefit of tacalcitol over calcipotriol has been its once-daily dosage, 
although recent findings showed that once-daily dosing of calcipotriol cream 
might  have  similar  efficacy  to  twice-daily  applicationCalcitriol  might  have 
better tolerability than calcipotriol in treatment of easily irritated areas such as 
the face, hairline, and flexural areas.The major theoretical benefit of calcipotriol 
is its limited effect on calcium homeostasis, although all three vitamin D^sub 3^ 
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derivatives have been shown to be safe when used in their respective dosage 
regimens for periods of up to 1 year Lesional or perilesional skin irritation with 
vitamin  D  analogues,  manifesting  as  pruritus,  burning,  oedema,  peeling, 
dryness, and erythema, is seen in up to 35% of patients and seems to be reduced 
with  ongoing  treatment.  Although  clinically  relevant  hypercalcaemia  and 
parathyroid hormone suppression are rarely seen, some authors still recommend 
that  calcium concentrations  in  serum should  be  monitored  in  patients  with 
decreased renal function and impaired calcium metabolism.
An undoubted benefit  of vitamin D analogues is their value in combination 
therapy,  thus  allowing  for  a  reduction  in  the  dose  and  duration  of  other 
antipsoriatic agents (acitretin, ciclosporin,broadband-UVB, narrowband-UVB, 
and photochemotherapy [psoralens and UVA; PUVA]and, hence, potential to 
improve the risk-benefit ratio for these treatments. Furthermore, several studies 
have proven marked benefits of using vitamin D analogues in combination with 
topical  corticosteroids  in  various  maintenance  regimens.  For  example, 
maintenance with a vitamin D analogue was shown to be safe and effective 
after an initial period of a combination regimen of corticosteroid in the morning 
and a vitamin D analogue at night. Also, the addition of calcipotriol ointment on 
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weekdays to a weekend pulse-therapy regimen of potent corticosteroids might
 increase the duration of remission.
Additionally,  interest  in  the  corticosteroid-sparing  ability  of  vitamin  D 
analogues has facilitated the development of a new single agent first-line topical 
therapy for plaque psoriasis. Large, well-controlled studies have established the 
superior efficacy of a once-daily combination ointment containing calcipotriol 
and betamethasone dipropionate over use of either agent alone. Side-effects of 
corticosteroids and vitamin D analogues are minimised in clinical use for up to 
1 year by use of this combination
Tazarotene
Tazarotene is the only topical retinoid (vitamin A derivative) available for the 
treatment of plaque psoriasis. Available in gel or cream formulations, applied 
once daily, usually at bedtime, it is only moderately effective as monotherapy, 
and therefore is predominantly used in combination. For instance, vitamin D 
analogues and moderate or potent topical corticosteroids all provide an additive 
effect,  with  reduced  steroid  atrophogenicity.  In  clinical  practice,  tazarotene 
seems to be less effective than calcipotriol, with a greater incidence of local 
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irritation (personal observations).
Because of its teratogenic potential, tazarotene is not given during pregnancy, 
and in women of childbearing potential should be restricted to localised plaques 
only. Up to 20% of patients have local skin irritation, which can be minimised 
with use of cream formulation, low concentration, application on alternate days, 
short contact (30 min to 1 h), mild cleansers, and combination therapy with a 
mid-potency topical steroid in the morning.
Dithranol
Although a mainstay of the treatment of psoriasis for over 80 years, the use of 
dithranol (also known as anthralin) has fallen steadily with the advent of more 
cosmetically  acceptable  drugs.  Recent  investigative  work  has  revealed  that 
dithranol's  mechanism  of  action  is  via  a  direct  effect  on  mitochondria.  As 
monotherapy, it has lower efficacy than either topical corticosteroids or vitamin 
D3 derivatives.However,  when used with UVB phototherapy in the regimen 
proposed by Ingram, greater improvement is seen than with UVB alone. The 
addition  of  intermittent  high  potency  topical  corticosteroids  minimises 
irritation43 and enhances  efficacy  without  shortening duration  of  remission. 
Furthermore, twice-daily calcipotriol added to short-contact 2% dithranol 
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ointment markedly augments the efficacy and tolerability of dithranol.
Because it causes substantial skin irritation and staining of skin ,clothing, and 
furniture, dithranol is best used in hospital or in day treatment centres. Short 
contact applications of high-dose dithranol for up to 30-60 min a day has shown 
similar efficacy to longer applications and even twice-daily calcitriol ointment. 
Application of triethanolamine after removal of dithranol might reduce irritation 
and staining of the skin. Newer formulations of dithranol might allow better 
tolerance.
Coal tar
Coal tar, a mixture of thousands of compounds, has been used in the treatment 
of psoriasis for more than a century. Available in ointments,  shampoos,  and 
solutions, crude coal tar is the most effective form available and, like dithranol, 
is commonly used in hospital or day-care settings. The combination of coal tar 
with UVB as described by Goeckerman has shown greater efficacy than UVB 
alone.. Skin irritation, folliculitis, odour, and staining of clothing limit coal tar's 
use as a routine outpatient treatment, in addition to its oncogenic potential.
Systemic treatments
Traditional systemic agents have been available for psoriasis since methotrexate 
was  first  approved  by  the  US  Food  and  Drug  Administration  in  1971  and 
remain the mainstay of treatment for patients with moderate to severe disease 
and those unresponsive to topical agents or phototherapy. Additionally, patients 
may be suited to systemic treatment if they have physical restrictions (eg, hand 
or  foot  psoriasis,  associated  psoriatic  arthritis)  or  significant  quality  of  life 
issues. All patients should receive a full physical examination; depending on the 
choice of agent, issues such as HIV status, presence of hepatitis, and previous 
systemic  cancers  should  be  considered  before  initiating  therapy  .Biological 
therapies now provide new options for patients who previously were intolerant 
of or unresponsive to traditional systemic agents.
Methotrexate
Methotrexate, as a folic acid antagonist,  interferes with purine synthesis and 
thus  inhibits  DNA synthesis  and  cell  replication;  it  also  has  specific  T-cell 
suppressive  activities.  Despite  the  advent  of  new  therapies,  methotrexate 
continues to play a central role as an affordable, gold standard treatment for 
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recalcitrant psoriasis and psoriatic arthritis.
Despite its widespread use, only recently has the efficacy of methotrexate in 
treating  moderate-to-severe  psoriasis  been  established  in  head-to-head  trials 
against ciclosporin. Methotrexate is usually prescribed orally in a once-weekly 
single-dose or three-divided-dose schedule over 24 h, after a 2.5-5 mg test dose, 
in doses ranging from 7.5 mg to 22.5 mg per week, pending clinical response. 
Oral  folic  acid  1.5  mg  daily  is  added  to  prevent  stomatitis  and  macrocytic 
anaemia and to decrease gastrointestinal symptoms, such as nausea, vomiting, 
and  anorexia;  however,  it  may  reduce  the  efficacy  of  methotrexate.  When 
stability  or  adequate  clearance  is  achieved,  the  lowest  effective  dose  of 
methotrexate should be sought by tapering the dose slowly by about 2.5 mg per 
month.
Methotrexate  has  the  potential  for  severe  side-effects,  necessitating  careful 
selection  and  monitoring  of  patients.  Firstly,  because  of  its  teratogenicity, 
methotrexate  is  absolutely  contraindicated  during  pregnancy,  and  pregnancy 
should  be  avoided for  at  least  3  months  after  discontinuing treatment.  Men 
whose partners are considering conception should also avoid methotrexate for 
this period of time. Bone marrow suppression is the most common cause of 
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death  attributable  to  this  treatment;  hence,  appropriate  screening  every  1-3 
months is essential.  A rare complication of methotrexate therapy, pulmonary 
fibrosis, seems to be less common in psoriasis than in rheumatoid arthritis.By 
contrast,  with long-term use,  methotrexate  seems more  likely  to  cause  liver 
fibrosis  and  cirrhosis  (damage  not  reliably  detected  with  liver  enzymes  or 
imaging)  in  patients  with  psoriasis  than  in  those  with  rheumatoid  arthritis. 
Current guidelines recommend a liver biopsy after a cumulative methotrexate 
dose of 1-5 g and then after every subsequent 1-5 
Methotrexate  can  also  be  used  as  combination  therapy  with  ciclosporin,  as 
described for rheumatoid arthritis, with little apparent increase in side-effects; 
this  combination  seems  particularly  prevalent  in  patients  with  concomitant 
psoriatic  arthritis.  The  effectiveness  of  methotrexate  in  combination  with 
tumour  necrosis  factor  α  (TNFα)  blocking  agents,  as  used  in  rheumatoid 
arthritis and psoriatic arthritis, has yet to be validated in psoriasis.
Retinoi  ds  
Oral  retinoids  (vitamin  A  derivatives)  have  been  used  in  the  treatment  of 
psoriasis for the past two decades. These synthetic hormones bind to nuclear 
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retinoid receptors, thereby altering gene transcription and returning keratinocyte 
proliferation  and  differentiation  to  normal.  The  original  third  generation 
retinoid used for psoriasis, etretinate, was superseded by its natural metabolite, 
acitretin,  which  was  shown  to  have  similar  efficacy  with  a  better 
pharmacokinetic profile. As a monotherapy, treatment is normally started with a 
dose of 10-25 mg acitretin, with dose adjustments dependent on response and 
side-effects. 
Systemic retinoids are especially effective in the treatment of erythrodermic and 
pustular variants of psoriasis, Since they are not immunosuppressive, retinoids 
might have a role in the treatment of psoriasis in children, patients with HIV 
infection, and those that are prone to cancer. Retinoids are considered excellent 
for  use  in  combination  with  other  treatments  and  when used  with  UVB or 
PUVA, their dose and the number of phototherapy treatments can be reduced, 
with  the  added  benefit  of  a  potential  reduction  in  skin  carcinogenesis. 
Furthermore, systemic retinoids can also be combined or used sequentially with 
most other systemic and biological agents.
Systemic  retinoids  should  be considered with extreme caution in  women of 
childbearing potential because of teratogenicity. Women taking acitretin should 
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avoid pregnancy during treatment with acitretin and for 2 years (3 years in the 
USA) afterwards. Alcohol re-esterifies acitretin to etretinate, a potent teratogen; 
therefore, women should be cautioned about alcohol consumption while on this 
treatment.
Systemic  retinoid  toxicity  is  similar  to  hypervitaminosis  A;  hence, 
mucocutaneous side-effects (eg, cheilitis, skin dryness, conjunctivitis, and hair 
loss)  are  common.  Other  side-effects  include  hyperlipidaemia  (especially 
triglycerides),  osteoporosis,ligamentous  calcifications,  and  skeletal 
abnormalities, including diffuse idiopathic skeletal hyperostosis syndrome. Rare 
side-effects include retinoid hepatitis and pseudotumour cerebri.
Ciclosporin
Ciclosporin, as serendipitously discovered in 1979 during a study of its efficacy 
in arthritis, is a useful short-term treatment for moderate-to-severe psoriasis, but 
is  less  effective  for  active  psoriatic  arthritis.It  is  a  macrocyclic 
immunosuppressant  that  binds  immunophilin  and  inhibits  the  calcineurin 
phosphatase-initiated activation of T cells; it may also exert a direct effect on 
epidermal keratinocytes.
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Ciclosporin therapy is carefully tailored to the individual patient with severe 
inflammatory or recalcitrant psoriasis. The recommended initial dosage is 2.5 
mg/kg per day, although very active disease can necessitate starting with higher 
doses; dose adjustments are then made every 2-4-weeks up to a maximum of 5 
mg/kg per day. Ideally, therapy should be restricted to intermittent short courses 
of  12  weeks  duration.  Ciclosporin  is  highly  effective  in  inducing  a  rapid 
remission of psoriasis; longer-term treatment at doses of about 3 mg/kg per day 
effectively maintains remission.
Unlike methotrexate,  ciclosporin is neither teratogenic nor myelosuppressive, 
but  requires  careful  monitoring  for  nephrotoxicity  and  hypertension.. 
Additionally, an increased risk of non-melanoma skin cancer exists, especially 
in patients previously treated with PUVA. Ciclosporin may lead to treatable 
laboratory  abnormalities  (hyperlipidaemia,  hypomagnesaemia,  and 
hyperkalaemia),  hypertrichosis,  gum  hyperplasia,  and  gastrointestinal  and 
neurological  disturbances.  If  concentrations  of  creatinine  in  serum  increase 
above 30% from baseline,  ciclosporin doses should be lowered accordingly. 
Early hypertension can be treated with a calcium channel blocker (which may 
prevent nephrotoxicity), a thiazide diuretic, or an angiotensin-converting 
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enzyme inhibitor.
Ciclosporin  is  commonly  used  in  combination  or  in  rotation  with  other 
treatments for psoriasis, including low-dose methotrexate or acitretin and other 
agents such as mycophenolate mofetil, fumarates, sulfasalazine, and biological 
agents.
Fumari  c acid esters  
Oral fumaric acid esters (fumarates) have been used to treat severe psoriasis in 
Europe for  more  than 40 years,  especially  in  Germany,  after  initially  being 
reported  on  in  1959  by  a  German  chemist  who  hypothesised  and  then 
demonstrated the benefits of fumarate therapy on his own psoriasis. Fumarates 
are naturally occurring molecules that link the urea and citric acid cycles, with 
their benefit in psoriasis now considered to be consequent mainly due to NFκB 
inhibition and T-cell apoptosis.
A commercially available mixture of four fumaric acid esters has been shown in 
a systematic review to be a highly effective treatment for psoriasis, with PASI 
reductions  approaching  those  reported  for  methotrexate  and  ciclosporin. 
Unfortunately, despite an absence of severe adverse events, the fumarates may 
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cause  markedly  unpleasant  gastrointestinal  symptoms,  including  abdominal 
cramps, diarrhoea, and nausea, as well as flushing, fatigue, and pruritus; these 
effects are probably seen more with high doses.
Biological agents
An  appreciation  of  the  immune  pathways  critical  to  the  pathogenesis  of 
psoriasis has led to the development of new agents that target these specific 
steps.  Biological  agents  are recombinant  molecules that  are designed on the 
basis of genetic sequences from various organisms and that are often similar or 
identical to proteins produced by human beings. They include fusion proteins, 
recombinant  proteins  (eg,  cytokines,  selective  receptors),  and  monoclonal 
antibodies,  and  are  common  treatments  for  autoimmune  diseases  such  as 
rheumatoid arthritis and Crohn's disease (table 3). Psoriasis, a more common 
systemic  disease  with  similar  quality-of-life  issues,  has  finally  joined  the 
biological revolution.
T-cell agents
Alefacept
Alefacept112 was the first biological agent specifically designed and approved 
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for the treatment of psoriasis (in 2003, in the USA). It is a human leucocyte 
function associated antigen-3/IgGl fusion (recombinant)  protein that binds to 
CD2 on memory effector T cells, selectively interfering with the function of 
antigen  presenting  cells  and,  hence,  T-cell  activation.  An  additional  and 
important  mechanism  of  action  is  apoptosis  of  memory-effector  CD45RO-
positive T cells in the skin. 20% of patients achieve a 75% reduction in PASl 
(PASI  75)  after  a  12-week  cycle  of  weekly  intramuscular  injections  of 
alefacept.  Furthermore,  a  small  proportion  of  patients  have  maintained  a 
lengthy clinical response after the cessation of treatment (median duration 241 
days).  Improvement  in  psoriasis  seems  to  correlate  with  a  reduction  in  the 
number  of  memory-effector  CD45RO-positive  T  cells  in  peripheral  blood. 
Subsets  of  CD4-positive  and  CDS-positive  T  cells  in  peripheral  blood  are 
monitored on a fortnightly basis during the 12-week treatment cycles.  Toxic 
effects  on  organs  such  as  those  seen  with  methotrexate,  ciclosporin,  and 
retinoids, are virtually absent.
Efalizumab
Efalizumab is a humanised monoclonal  antibody that  binds to the α subunit 
(CD11a) of leucocyte function associated antigen-1, thereby inhibiting 
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activation of T cells and adhesion between T cells and endothelial cells, which 
prevents  circulating  T  cells  from entering  the  skin.  It  is  administered  as  a 
weekly subcutaneous injection,  at  0.7 mg/kg for  the first  dose and 1 mg/kg 
thereafter. The most frequent short-term adverse effect is a flu-like syndrome 
occurring in the first  2 weeks of treatment.  The only toxic effect  on organs 
seems to be rare  occurrences  of  thrombocytopenia and haemolytic  anaemia, 
necessitating monitoring of platelet counts.
Up to 20% of patients may develop a transient papular flare of psoriasis on the 
trunk and body folds, which is easily managed with topical therapy. However, a 
more striking generalised inflammatory flare occurs in up to 5% of patients, 
particularly those who are not responsive to therapy at 6-10 weeks after starting. 
Such flares might necessitate active intervention with systemic therapies such 
as methotrexate or ciclosporin or discontinuation of efalizumab.
TNFα inhibitors
Etanercept
Etanercept, a human recombinant TNF receptor p75 protein that binds to TNFα 
and β, is self-administered subcutaneously at a dose of 25 mg twice weekly 
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Very importantly, etanercept also relieves fatigue and symptoms of depression 
in patients with moderate-to-severe psoriasis. Etanercept is highly effective in 
psoriatic arthritis, with a reduction in the signs and symptoms of joint disease in 
73-87% of  patients  at  12  weeks  of  treatment,  with  a  parallel  inhibition  of 
radiographic progression of disease.
Infliximab
Infliximab is a chimeric monoclonal antibody that binds to and neutralises the 
activity of TNFα. In psoriasis, infliximab is given as an intravenous infusion, 
optimally in a dose of 5 mg/kg over 2-3 h at weeks 0, 2, and 6, and at regular 8-
week intervals thereafter. 
Adalimumab
Adalimumab  is  a  fully  human,  anti-TNFα  monoclonal  antibody,  self-
administered subcutaneously in a dose of 40 mg on alternate weeks. As with the 
other anti-TNFα agents, structural changes on radiographs in patients with joint 
disease  were  prevented  and  disability  significantly  reduced.Patients  had 
substantial improvements in their quality of life.
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Side-effects
Data  from  clinical  and  post-marketing  studies  on  these  agents  are 
predominantly derived from non-psoriasis patients and may not be applicable to 
psoriasis  and psoriatic  arthritis  due to  different  comorbidities  in  this  patient 
population,  as  well  as  the  fact  that  overwhelmingly  psoriasis  and  psoriatic 
arthritis patients are treated with monotherapy. In a recent meta-analysis of nine 
clinical  trials  using infliximab  and adalimumab  for  rheumatoid  arthritis, the 
authors emphasised the need for vigilance with respect to cancer and serious 
infections. Traditionally, because of the role of TNFα in granuloma formation, 
infections such as tuberculosis, histoplasmosis, and coccidioidomycosis require 
careful  monitoring,  with  appropriate  tuberculosis  screening  indicated  in  all 
patients before treatment with TNFα antagonists.
Other important  issues  common to this  class  of  agents are rare instances of 
demyelinating  conditions,  including  optic  neuritis;  and  the  exacerbation  of 
cardiac failure in patients with a history of moderate to severe cardiac failure. 
The incidence of infections is possibly slightly greater with the two antibodies, 
infuximab and adalimumab, than with the fusion protein etanercept. Liver 
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toxicity should also be considered; recently completed phase III studies with 
infliximab showed that about 5% of patients had substantial (fivefold) increases 
in hepatic enzymes.
Future treatments
Although biological treatments have been a great advance in the management of 
psoriasis, their exact place in the hierarchy of systemic therapies will not be 
known until controlled trials have compared them against each other and with 
traditional approaches.
Research over the next decade will reveal new, specifically targeted biological 
therapies  for  the  management  of  inflammatory  immune-mediated  diseases, 
including psoriasis. Anti-interleukin 12/23 agents have shown great promise in 
phase II and III studies, with significant clinical improvement noted in psoriasis 
after  a  single  subcutaneous  injection.  Other  cytokines  identified  as  key 
proinflammatory  determinants  of  psoriasis  will  also  be  targeted  with 
opportunity  for  regulatory  cytokine  approaches,  such  as  introducing  Th2 
cytokines (including interleukin 4 and interleukin 10) to restore the Thl/Th2 
balance in what is essentially a ThI disease. Pan-selectin and T-cell-specific 
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targeting  are  other  potential  approaches  to  psoriasis  management.  Small 
molecule technology might facilitate the administration of oral as opposed to 
injectable agents targeting TNFα and T-cell activation and signalling pathways.
New generation systemic calcineurin inhibitors such as pimecrolimus seem to 
be effective with negligible side-effects, such as hypertension or nephrotoxicity, 
over  the  course  of  12-week  studies.However,  concerns  about  a  possible 
increased  risk  of  lymphoproliferative  disease  have  delayed  the  further 
development of oral pimecrolimus. Another oral calcineurin inhibitor, ISA247, 
was tested for 12 weeks in psoriasis,  resulting in 67% of patients in the 1-5 
mg/kg per day dose group achieving PASI 75. Serum creatinine increased in 
patients treated with ISA247 1.5 mg/kg/day but remained within the normal 
range.141  An  enteric-coated  formulation  of  a  single  active  fumarate, 
dimethylfumarate, has been shown to be highly promising and less toxic than 
fumarates.  Pharmacogenetics  has  shown  that  polymorphisms  in  thymidilate 
synthetase, a key enzyme in the methotrexate metabolic pathway, might predict 
response to and side-effects from methotrexate in psoriasis. Polymorphisms in 
the gene for vascular endothelial growth factor could predict patients' responses 
to systemic retinoid treatment. We predict that the research interest in 
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angiogenesis  in  psoriasis  will  lead  to  the  selective  targeting  of  angiogenic 
factors, such as vascular endothelial growth factor, as is already happening in 
oncology. In the midst of this innovation, it should be acknowledged that to 
enhance  the  efficacy  and  reduce  the  side-effects  of  traditional  systemic 
treatments is of pharmacoeconomic interest.
Phototherapy and photo chemotherapy play a major role in chronic psoriasis. 
The mechanism of action of ultraviolet B (311 – 313 nm) seems to be depletion 
of T cells, particularly those in the epidermis by apoptosis and a shift from Th1 
to Th2 immune response in lesions.  UVB phototherapy can be combined with 
prior application of coal tar.  Patients of stable psoriasis with more than 20% 
body surface area affection can be treated with Narrow-band UVB.  PUVA in 
psoriasis  acts  by  suppressing  DNA  synthesis  and  cellular  proliferation  and 
inducing  apoptosis of cutaneous lymphocytes.  The 308nm exicmer laser emits 
a monochromatic and coherent beam in the UVB spectrum and delivers high 
fluencies selectively to a lesion while sparing the surrounding healthy skin. [44]
Physical treatments, such as the excimer and pulsed dye lasers, might be useful 
treatment modalities for localised, recalcitrant plaques of psoriasis. The excimer 
laser  delivers high-energy 308 nm monochromatic  UVR and has advantages 
over conventional UVR sources in that surrounding (normal) skin is untreated. 
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Side-effects include substantial erythema and blistering at treatment sites and 
residual  hyperpigmentation.  Studies  of  pulsed  dye  lasers  in  psoriasis  report 
between 57% and 82% response rates, and remission may extend to 15 months.
Psoriasis is currently an incurable disease that affects individuals differently. 
Maintenance of long-term safe control with important quality-of-life issues is 
paramount. The use of new treatments-physical, biological, or pharmaceutical-
should not be a substitute for a detailed evaluation and discussion with patients 
to ascertain their expectations. Indeed, the management of psoriasis is still very 
much a mix of art and science.
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PHOTOTHERAPY
History
The first report of the use of ‘phototherapy’ in the treatment of skin disorders 
dates from 1400BC from India when patients with vitiligo were given certain 
plant extracts (whose active ingredients included psoralens) and then exposed to 
the sun.[45] The real  interest  in the use of  ultraviolet  (UV) irradiation in  the 
treatment of various skin diseases started in the 19th century when Niels Finsen 
received the Nobel Prize (1903) for his therapeutic results with UV irradiation 
in  lupus  vulgaris,  the  only  dermatologist  ever  to  be  awarded  one. [46] This 
marked the start of modern phototherapy. It was used in thermal stations for the 
treatment of tuberculosis, in the treatment of leg ulcers in wartime, and various 
other skin diseases. [47] It was a very long journey from the use of plant extracts 
and sun exposure to treat vitiligo to the use of oral psoralens and total body 
UVA-irradiation cabins (PUVA) to treat various skin diseases. In a landmark 
development,  in 1974 Parrish et al  reported the useful  role of high intensity 
UVA tubes in combination  with oral  psoralens in the treatment  of  psoriasis 
leading  to  what  is  now  known  as  PUVA  therapy. [48].The  history  of  UVB 
phototherapy is not as old as the history of photochemotherapy. Wiskemann 
introduced irradiation cabin with broad band UVB tubes in 1978 for the 
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treatment  of  psoriasis  and  uremic  pruritus.[49] However,  broad  band  UVB 
phototherapy was less efficient for treating psoriasis than PUVA and so never 
achieved  popularity.  The  breakthrough  came  after  1988  when  narrow-band 
UVB (NB-UVB) phototherapy was introduced for the treatment of psoriasis by 
van Weelden et al and Green et al. [50,51]
Phototherapy refers to the use of ultraviolet light for the treatment of various 
skin  disorders.   The  ultraviolet  light  refers  to  the  electromagnetic  spectrum 
between 200nm to 400nm.  The wavelength in the range of 200 to 290nm are 
referred to as UVC and this do not reach the earth’s surface at sea level and the 
energy is absorbed by the ozone layer in the stratosphere.  Moreover UVC 
region of spectrum is called Germicidal radiation which is lethal to the liable 
cells of the epidermis.
The next range between 290 to 320 nm is known as UVB and referred to as 
mid-UV or sunburn spectrum, wherein the most erythmogenic wavelengths of 
this spectrum reach the earth’s surface . Most sunscreens work efficiently at 
minimizing the effects of this waveband.  Infact, the sun protection factor (SPF) 
is actually based on testing against this waveband.
The long wave ultraviolet.  A spectrum between 320- to 400 nm is referred to as 
black light because it is not visible to the human eye and causes certain 
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substances to emit  visible fluorescence.   UVA has been divided into UVA-I 
(340 to 400 nm) and UVA-II (320 to 340 nm) because the later band is more 
damaging to unsensitised skin than the longer wavelengths.
Response of skin to Ultraviolet radiation(UVR)
Skin is affected by UV and visible radiation that is absorbed by molecules in 
skin.  In the first step, molecules in skin such as pyrimidine nucleotides, DNA 
(eg.  Thymidine,  cytosine)  and  urocanic   acid  absorb  radiation.   A  light 
absorbing  molecule  is  referred  to  as  a  chromophore.   In  some  cases,  the 
chromophore is an exogenous agent such as an ingested photosensitizing drug 
for example, tetra cycline or 8-methoxypsoralen.  After absorbing the energy of 
the radiation,  the  chromophore  is  in  an  excited state.   Although this  highly 
energetic species exists for only a fraction of a second, a chemical change may 
occur during this time to transform the molecule into a photoproduct such as an 
oxidized membrane lipid [52,53] pyrimidine dimer  [54]or psoralen-DNA adduct[55]. 
The  presence  of  photoproducts  in  cells  provokes  biochemical  responses, 
beginning with signal transduction processes and further activate transcription 
factors such as AP-1 [56,57]and NF-KB[58,59] and thereby initiate cellular synthesis 
of  new  proteins,  for  example,  melanin[60,61] cytokines[62  -  64]and  matrix 
metalloproteinase-1[65,66]Other important processes such as repair of UV-
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induced DNA damage also occur [67,68]  These biochemical responses culminate 
in cellular effects such as proliferation, secretion of cytokines and apoptosis that 
are observed as acute skin responses.
The  specific  wavelengths  of  UV  or  visible  radiation  absorbed  by  these 
molecules are called absorption spectra.   The wavelengths that have highest 
probability of absorption are called absorption maxima, __.max and are used as 
identifying characteristics of a compound
 (eg. DNA __max = 260 nm, Porphyrin __max = 400 to 420 nm)
UV Radiation Dosimetry
The basic unit of energy is the Joule (J)
Power  is  the  rate  of  energy  flow given  in  watts(W)  or   Joules  per  second 
(W=J/s) 
The power delivered per unit area of surface is called Irradiance [W/cm2 = (J/s) 
per cm2] 
The total radiant energy delivered per unit area of skin surface is expressed as 
‘Exposure dose’ or ‘Fluence’.  (Exposure dose = Irradiance x time = J/cm2)
Acute effects of UVR
UVB causes considerable DNA damage in the basal layer, but UVA also 
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induce epidermal cyclobutane pyrimidine dimers with much higher doses.  The 
tumor suppressor p53 protein is not detectable in normal human epidermis but 
is readily induced by a single exposure to UVR.  This protein which acts as a 
transcription factor reduces cell cycle (G1) arrest to allow time for the repair of 
DNA  photolesions  thus  minimizing  the  transfer  of  potentially  carcinogenic 
mutations to daughter cells.
Erythema (Sun burn inflammation) is the most recognized acute cutaneous 
response to UVR and is associated with classical signs of inflammation namely, 
redness, warmth, pain and swelling.  Erythema is UVR dose dependent, solar 
range UVB (300 nm and 313 nm) and UVA (365 nm) erythemas having similar 
slopes ,although the slopes for UVC (254 nm) and non solar UVB (280 nm) are 
much  less  steep  [69]Erythemal  effectiveness  declines  rapidly  with  increasing 
wavelength, with for example 360 nm (UVA) radiation requiring 1280 times 
more  energy  than  300  nm  (UVB)  radiation  to  produce  the  same  effect. 
Therefore, the relatively small UVB component & solar UVR accounts for the 
majority of its erythermal effect.  DNA is a major chromophore for erythema.
UVR exposure induces the synthesis and release of an extensive array of 
mediators including histamine, by-products of arachidonic metabolism, pro-
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inflammatory  and  immuno-suppressive  cytokines,  chemokines,  adhesion 
molecules,  growth  factors  and  neurotransmitters  all  of  which  profoundly 
influence the biological function of the skin.
UVR  exposure  suppreses  cutaneous  cell-medicted  immunity  in  humans. 
The depletion of langerhans cells, the principle antigen-presenting cells in the 
epidermis,  recruitment  of  macrophages  into  the  dermis  and  epidermis  and 
release  of  inflammatory  mediators  such  as  TNF  -  alpha,  IL-10,  TGF-beta, 
alpha-MSH and CGRP, are all important events in the initiation of 
immunosuppression.   Susceptibility  to  UVR-induced  immunosuppression 
appears to be skin-type dependant.  Skin phototypes I/II are at greater risk of 
skin cancer and are also more readily immunosupressed than patients of skin 
phototypes  III/IV.   DNA seems  to  be  an  important  chromophore  for  UVR 
induced immunosuppression.
Tanning may be true melanogenesis known as delayed tanning or immediate 
pigment darkening.  IPD is believed to result from photo-oxidation of existing 
melanins  and redistribution of  melanocytic  melanosomes  from a perinuclear 
position  into  the  peripheral  dendrites.   Delayed  tanning  following  UVR 
exposure is the result of increased epidermal melanin formation, the pigment 
becoming visible within days after UVB exposure.  With exposure to longer 
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UVA wavelengths, tanning occurs earlier.  UVB delayed tanning is associated 
with  an  increased  in  the  activity  of  melanocytes  while  repeated  doses  are 
required to increase numbers.
The  rate  limiting  enzyme  in  melanogenesis  is  tyrosinase  and its  activity 
correlates  closely  with  the  melanin  content  of  cultured  pigment  cells  and 
increases during tanning.
Chronic effects of UVR
A relationship between solar exposure and all types of skin cancer has been 
established and animal studies have shown that UV irradiation induces early 
epidermal apoptosis  in the form of highly characteristic sunburn cells that are 
apparent  within  30  min  of  exposure  and  maximal  at  24  hours.   DNA 
photodamage is the immediate acute effect that initiates a chain of molecular, 
mutational,  cellular  and  immunologic  events  that  lead  to  a  skin  tumor, 
especially non-melanoma skin cancer.
Photoaging  as  a  result  of  UVR  induced  tissue  degrading  matrix 
metalloproteinases are well known and clinically characterized by dry  deeply 
wrinkled,  inelastic,  leathery,  telangiectatic  skin  and  often  with  irregular 
pigmentation, freckling and lentigo formation (dermatohelosis)
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PUVA Photochemotherapy
 Psolaren plus UVA (PUVA) photochemotherapy is the photochemical interaction
  between psolaren and ultraviolet A.
Psolarens  are  naturally  occurring  compounds.   Methoxsalen  (8-methoxy 
psoralen)  is  obtained  from  the  seeds  of  a  plant  Ammi  majus.   Psolarens 
intercalate between DNA base paris without UV radiation [70 - 72].Absorption of 
photons in the UVA range results in the formation of a 3,4 or 4,5 cyclobutane 
addition  product  with  pyrimidine  bases  of  native  DNA.This  intercalation  of 
psoralens with epidermal DNA produces a suppression of both DNA synthesis 
and cell division which may be the possible therapeutic mechanism in psoriasis.
Oral  psoralen is absorbed by the GI tract and increased photosensitivity is 
present one hour after the dose, reaches a peak at about 2 hours and disappears 
by eight hours[73]  Psoralens are metabolized in the liver by hydroxylation and 
glucronide  formation  and  over  90%  is  excreted  in  the  urine  within  12 
hours[74].Methoxsalen has a serum half-life of approximately one hour and is 
rapidly eliminated which prevents photosensitivity[75]
PUVA  causes  photoconjugation  of  psoralens  to  DNA  and  subsequent 
suppression in mitosis,  DNA synthesis,  cell  proliferation and immunological 
alterations.  A decrease in the percentage of circulating T-lymphocytes 
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following PUVA treatment has been reported[76]
Sources of UVA radiation
UVA sources commonly used for PUVA therapy are fluorescent lamps or 
high pressure metal halide lamps.  The PUVA lamp has an emission peak at 352 
nm and emits approximately 0.5% in the UVB range.  UVA doses are given in 
J/Cm2 and are measured with a photometer. 
Narrow-Band UVB   Phototherapy   
A potential advance in UVB – based phototherapy has been the introduction 
of fluorescent bulbs (Philips model-TL-01) that deliver UVB in the range of 
310 to 313 nm, with a peak at 312 nm.. It has a relatively narrow spectrum of 
emission which when compared with the older broad band UVB source has a 
reduction in erythemogenic wavelengths in the 290-305 nm range and 5-6 fold 
increased  emission  of  the  longer  UVB  wavelengths,  thereby  resulting  in  a 
higher phototherapy index for psoriasis.
Mechanism of action
In the skin , NB-UVB radiation is absorbed by  DNA and urocanic acid and 
alters antigen presenting cell activity. NB-UVB is about 5-10 fold less potent 
than broad band UVB for erythema induction, hyperplasia, edema, sunburn cell 
formation and Langerhans cell depletion from the skin. It has a relatively more 
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suppressive  effect  than  broad  band  UVB  on  systemic  immune  response  as 
judged  by  natural  killer  cell  activity,  lymphoproliferation  and  cytokine 
responses.  [77] The mechanism of action of NB-UVB photherapy has not been 
completely  understood.  In  psoriasis,  lymphocyte  proliferation  and  immune 
regulatory cytokine production is mediated by both Th1 ( IL-2, IFN-g) and Th2 
(IL-10) T-cell population [77,78]
Phototherapy Unit :
  NB-UVB phototherapy cabins contain fluorescent TL-01 (100W) tubes as 
the  source  of  irradiation.NB-UVB  cabins  available  commercially  either 
incorporate TL-01 alone or in combination with UVA tubes. Recently, shorter 
tubes  of  NB-UVB  have  also  become  available  in  small  area  treatment 
equipment (hand and foot unit,  NB-UVB comb) for the therapy of localized 
body areas.
Dosing schedule
NB-UVB schedules can be tailored according to patient skin type and local 
experience.  There  are  two regimens  that  are  most  commonly  used,  the  first 
involves determination of the individual’s minimum erythema dose (MED) by 
means of a separate bank of TL-01 tubes. Often 70% of the MED value is used 
for the first treatment; thereafter therapy is given three times or more in a week 
45
with 40, 20 or 10% increments depending on local experience and skin type 
tolerance.  Another  approach  ,  as  commonly  practiced  in  India,  involves  a 
standard dosing dose (280Mj),with stepwise increase (usually 20%)depending 
upon the patient’s erythema response. In the photodermatoses, the approach is 
more cautious with only 10% incremental  regimen in sunexposed sites[78] In 
case  of  mild  erythema,  the  irradiation  dose  is  held  constant  for  subsequent 
treatments or until resolution of symptoms. The goal of theraphy is to achieve 
persistent asymptomatic erythema. In case of painful erythema  with or without 
edema/  blistering,  further   treatment  is  withheld  till  the symptoms subside. 
After resolution of symptoms, the dose administered is 50% of the last dose and 
subsequent increments should be by 10%.
Narrow-band UVB in Psoriasis
 The NB-UVB lamp was developed as a ‘new’ UVB phototherapy source 
with  an  emission  spectrum  within  the  therapeutic  waveband  for  psoriasis 
phototherapy.
  NB-UVB phototherapy has a higher ratio of therapeutic to erythemogenic 
activity,  resulting  in  increased  efficacy,  reduced  incidence  of  burning  and 
longer  remission.   Results  from two therapeutic  action  spectroscopy studies 
indicated that wavelengths of the range 295-320 nm are effective in clearing 
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psoriasis,  whereas  shorter  wavelengths  are  more  erythemogenic,  and 
wavelengths  longer  than  320  are  less  therapeutic  [79,80]Subsequent  clinical 
studies  have  tended to  report  significantly  greater  improvement  of  psoriasis 
with  NB-UVB  including  reduced  incidence  of  burning  episodes,  increased 
efficacy  and  longer  remission  when  compared  with  broad  band  sources[81] 
When  NB-UVB  phototherapy  and  PUVA  were  compared,  there  was  little 
overall  difference  in  efficacy  [82,83] Coven  et  al  compared  the  therapeutic 
effectiveness  of  half-body  exposures  to  NB-UVB  or  broad  band  UVB  in 
moderate  to severe psoriasis.  [84] Clinical  resolution was achieved in 86% of 
sites treated with NB-UVB vs. 73% treated with broad band UVB including 
faster clearing and more complete disease resolution.  Although treatment with 
NB-UVB  is  reported  to  be  highly  effective  in  clearing  psoriasis  patients, 
whether this therapy represents a modest advance or a real breakthrough is not 
clear.  If NB-UVB is to replace PUVA therapy in the treatment of more severe 
psoriasis, it must not only achieve a comparable clearance rate in psoriasis, but 
it must also maintain remission at a comparable frequency of treatment.  At 
present, small studies do provide some hope in this respect.[85]
The  goal  of  phototherapy  is  complete  clearance  of  all  psoriatic 
lesions.Psoriasis,however , is a chronic disease and the remission induced by 
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UVB phototherapy is often transient. In a randomized, prospective, multicenter 
trial,post clearing phototherapy was found to significantly increase the disease 
free  interval  ,indicating  that  patients  may  benefit  from  maintenance 
phototherapy(24).On the other  hand,maintenance  therapy results  in  a  greater 
cumulative UVB dose ,increasing the risk of skin cancer and photoaging.It is 
therefore preferable , if possible,to maintain remissions with other anti-psoriatic 
modalities.To  minimize  potential  carcinogenic  risks  from  chronic  UVB 
phototherapy,a rotational therapeutic approach has been suggested.(25)
Oral psoralen with UVB for the treatment of psoriasis
Generally psoralen increases the sensitivity of skin to UVB and increases the 
minimal erythema dose [MED]. The light absorption spectrum for oral psoralen 
peaks  at  325  nm[86], but  the  absorption  spectrum  extends  into  the  shorter 
wavelengths of ultraviolet light in the UVB range. PUVA treatment using 335-
nm UVA is  twice  as  effective  as  with  365-nm UVA with  respect  to  both 
erythemogenicity  and  the  cumulative  dose  required  for  clearing  psoriasis; 
however,  335  nm  and  365  nm  are  equally  effective  if  delivered  in  equal 
erythema doses, suggesting that in human skin the antipsoriatic activity of 8-
MOP parallels its erythemogenicity [87]. The action spectrum for phototoxic 
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erythema after topical 8-MOP sensitization peaks around 330 nm [88].
Some, but not all, studies indicate that PUVB is more effective in treating 
psoriasis than UVB alone. In a study of 44 patients in which half are treated 
with  PUVB  and  other  half  with  PUVA,  PUVB  therapy  is  as  effective  as 
conventional PUVA in the treatment of stable, plaque-type psoriasis in patients 
with Fitzpatrick type-IV skin [89]. A significantly lower dose of UVB is required 
for clearance as compared with PUVA. In another study involving 100 patients, 
NbPUVB treatment of psoriasis is as effective as conventional PUVA  [90]. A 
1995  study  found  PUVB and  UVB phototherapy  equally  efficacious  in  the 
treatment of psoriasis;  however, those areas of the body treated with PUVA 
responded more rapidly and to a greater extent than areas exposed to UVB [91]. 
Oral psoralen works with NbUVB for the treatment of psoriasis
Some studies indicate that psoralen seems to work in synergistically with 
311-nm UVB (NbPUVB). The effect of psoralen in combination with nbPUVB 
has  been  studied  in  five  subjects  with  normal  skin  and  ten  patients  with 
psoriasis involving both forearms [92]. Treatment with oral 8-MOP augments the 
UVB erythema response at 6 hours after irradiation, but has no effect at 24-72 
hours. In eight of the nine patients who complete the trial, lesions of psoriasis 
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on the arms treated with PUVB clear before lesions on the arms treated with 
UVB alone. This study has shown that psoralen in combination with UVB has 
an erythema effect on normal skin and a therapeutic effect in psoriasis that is 
greater than the response to UVB alone.
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Materials and Methods
Seventeen patients of chronic plaque type psoriasis were enrolled in our study. 
A Baseline Total lesional severity scale (TLSS)to assess erythema, scaling and 
thickness were calculated and minimal erythema dose (MED) was determined 
for all the patients. MED was determined by standard method. A template with 
10 apertures of 1½ x 1½ cm2 were made over the back of a cotton suit. Cotton 
flaps  were  made  over  the  apertures  enabling  us  to  either  shut  or  keep  the 
apertures  open  by  using  Velcro.  The  source  of  Narrow-bandUVB  was  the 
whole body phototherapy unit with 24 Philips TL -01 bulbs(V Care medicals 
services Pvt Ltd). To determine MED a single panel in the whole body unit with 
6  bulbs  were   used.  All  the  apertures  were  kept  opened  and  the  back was 
irradiated with 250mj of Narrow-band-UVB. The first aperture was  closed and 
the remaining apertures were then closed one after the other after delivering 
50mj more than the previous aperture. The dosage schedule for Narrow-band-
UVB were 250mj, 300mj, 350mj,  400mj, 450mj, 500mj, 550mj, 600mj, 650mj 
and700mj. The readings were taken 24hrs after exposure. The dose at which the 
minimal perciptible erythema found was  considered as MED.
For every patient, two clinically characteristic lesions for assessment were 
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selected on either side of the body. Narrow-bandUVB was given on right half 
of  the body and the left  half  of  the  body was covered using a  suite  which 
covered one half of the body. Oral psoralen at a dose of 0.5mg/kg body weight 
was administered immediately to the patient and two hours later patients were 
exposed to narrowband UVB on the left half  of the body while the right half 
was covered using the same suite. The initial dose of starting the treatment was 
taken as 70% of MED. The dose was gradually increased at the rate of 10% 
increment of the previous dose.  The treatment was then given thrice weekly 
over a period of five weeks thereby completing a total of 15 sittings and the 
TLSS  scoring  was  determined  at  the  end  of  5th,  10th,  and  15th sittings 
respectively.
Inclusion criteria: 
Chronic plaque type psoriasis, patients not on other modalities of treatment with 
minimum three weeks  of  wash off  period and body involvement  more  than 
20%. 
 Exclusion criteria: 
Unstable  psoriasis,  erythrodermic  psoriasis,  pustular  psoriasis,  pregnancy, 
lactation, children under 12 years and body involvement <20% body surface 
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area. 
Statistical analysis
For each patient  an average score of erythema ,  scaling and thickness  were 
calculated for NbUVB as well as NbPUVB at the end of 5,10 and 15 sessions.
These values were compared using  WILCOXON TEST. P value < 0.05 was 
considered as statistically significant
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Results
A  total  of  seventeen  patients  were  studied.  The  age  range  of  the 
patients were between 31 years to 70 years with the mean age of 49 years. 
Of the seventeen patients, 15 were men and 2 were women. The duration of 
psoriasis varied between 2 years to 28 years with mean duration of 15 years. 
All these patients belonged to skin type IV / V 
The Minimal  Erythema dose  varied  between 250mj  to  950mj  with 
mean of  457mj. (Table I)
Of the seventeen patients, thirteen completed the study ,one patient 
was lost for follow-up ,three patients [2 patients by the end of 4 th treatment 
and  1  patient  by  the  end  of  8th treatment  ]  could  not  continue  due  to 
aggravation of psoriasis. The score of the patients who aggravated are shown 
in Table III
The severity  of the index lesion according to TLSS scoring before 
treatment and after five, ten and fifteen treatments were recorded as shown 
in table-I. The values when compared using Wilcoxon test (p value < 0.05) 
was considered as statistically significant. The statistical analysis is shown 
in Table II
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The total TLSS score of fourteen  completed patients at the end of five 
sittings is 132 (mean - 9.42) for NbUVB and  127(mean 9.07) for NbPUVB. 
The difference was not statistically significant. At the end of ten treatments 
the mean value was 5.76 for NbUVB and 4.92 for NbPUVB.     
There  was  statistical  significance  at  this  point  [p  value  =  0.006]. 
However by the end of our study, after fifteen treatments the mean value for 
NbUVB  and  Nb-PUVB  were  3.0  and  2.76  respectively  which  were 
statistically  not  significant.   Minimal  side  effects  like  erythema, 
pigmentation and pruritus were encountered during treatment as shown in 
Table IV
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Table I
TLS Scoring [  Erythema ( 0-5 ) + Scaling (0-5 ) + Plaque elevation (0-5 ) ]
S.No Age Sex MED
Baseline After 5 Treatments After 10 Treatments After 15 Treatments
NbUVB PNbUVB NbUVB PNbUVB NbUVB PNbUVB NbUVB PNbUVB
1 37 Male 750mj 13 13 9 9 5 5 2 3
2 62 Male 500mj 12 12 8 7 4 2 2 0
3 31 Male 500mj 15 15 12 11 7 5 3 3
4 70 Male 300mj 13 13 9 8 5 5 2 1
5 69 Male 950mj 14 14 11 8 9 7 7 7
6 57 Male 500mj 12 12 7 8 4 4 2 1
7 54 Male 250mj 15 15 13 11 8 7 5 6
8 34 Male 450mj 13 13 7 8 6 5 4 4
9 33 Male 300mj 13 13 8 8 5 5 4 2
10 59 Male 400mj 14 14 10 9 6 5 1 3
11 46 Male 500mj 13 13 10 9 6 5 1 3
12 51 Male 350mj 15 15 9 9 4 4 2 2
13 35 Female 300mj 14 14 8 10 7 7 3 2
14 48 Male 350mj 13 13 11 12 - - - -
Mean
49.0
0
457.1
4
13.50 13.50 9.42 9.07 5.76 4.92 3.00 2.76
NbUVB : Narrow band ultra-violet B
NbPUVB  : Psoralen + Narrow band ultra-violet B
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Table II
Paired Samples Statistics
Mean N
Standard 
Deviation
T Value p Value
Pair 1
(Base 
line)
NbUVB
NbPUVB
13.5000a
13.5000a
14
14
1.01905
1.01905
- -
Pair 2
(After 5
Sessions)
NbUVB
NbPUVB
9.4286
9.0714
14
14
1.82775
1.43925
1.000 0.336
Pair 3
(After 10
Sessions)
NbUVB
NbPUVB
5.8462
5.0769
13
13
1.57301
1.38212
3.333 0.006
Pair 4
(After 15
Sessions)
NbUVB
NbPUVB
2.9231
2.8462
13
13
1.70595
1.95133
.210 0.837
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Table III
3 patients of aggravation
S.NO AGE SEX MED
Number of 
completed 
treatments
Base line After four 
treatments
After eight 
treatments
Nb 
UVB
Nb 
PUVB
Nb 
UVB
Nb 
PUVB
Nb 
UVB
Nb 
PUVB
1 52 Male 300mj 4 12 12 13 14 - -
2 25 Male 250mj 4 13 13 14 15 - -
3 48 Male 350mj 8 13 13 11 12 15 15
Table IV
Side effects 
Adverse reactions Number of patients
Generalized 
Pigmentation
9 / 13 ( 69.23 % )
Burning / 
Erythema
4 / 13 ( 30.77 % )
Pruritus 6 / 13 ( 46.15 % )
Lichenoid 
eruptions
1 / 13 (7.69 % )
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MED DETERMINATION
READING AFTER 24 HOURS
BASE LINE – BEFORE TREATMENT
AFTER FIVE SESSIONS

AFTER TEN SESSIONS
AFTER FIFTEEN SESSIONS
Discussion
Phototherapy treatment for psoriasis has been extensively modified since the 
landmark  combination  of  UVB and topical  tar  emollient  was  introduced by 
Goeckerman in 1925.
Although  PUVA  is  considered  one  among  the  most  effective  therapeutic 
modality for psoriasis, it may causes nausea, requires the use of eye protection 
after treatment sessions, cannot be used during pregnancy, is contraindicated in 
patients with significant  hepatic impairment or taking warfarin or phenytoin, 
and requires the some what inconvenient previous administration of psoralen. 
Of  greatest  concern,  is  the potential  of  PUVA to cause nonmelanoma skin 
cancer after 160 to 200 lifetime treatments, which almost certainly exceeds by 
some  margin  that  of  a  comparable  number  of  NB-UVB  sessions  [93,94] and 
certainly of broadband UV-B sessions[95].
NbUVB has not been uniformly effective for all  cases of chronic psoriasis  . 
Similarly PUVA also has failure rates. Since the absorption spectra of psoralen 
(325nm) is  closer  to  311nm,  and considering the  emission  spectra  of  TL01 
lamps of 311nm, it is possible that NbUVB may be effective like PUVA when 
combined with psoralen.
It is also possible that the combination of Psoralen and  NbUVB  may reduce 
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the dose required of either  psoralen or NbUVB or both thus minimizing the 
side effects. UVB is mostly effective when administered three times a week, 
whereas PUVA is usually administered twice a week[95] . Thus it is possible that 
combination might also reduce the frequency of phototherapy thereby reducing 
the inconvenience, the cost and reduction in total cumulative dose of NbUVB.
The mean age in our study was 49 years out of which 15 were men and 2 were 
women. Our patients belonged to Type IV/ V/ VI skin (one – IV, fourteen- V, 
two  -VI).  The  mean  MED  of  our  study  was  457mj.  Various  studies  have 
recorded different values of MED depending on the patient’s skin type. In a 
study done by Serisha et al MED values of 33 individuals ranged from 300mj to 
1700mj with mean MED of 714.15mj/cm2 whereas in another study conducted 
among the  Caucasian skin on 11 patients with psoriasis of skin types I, II and 
III the MED for NbUVB ranged from 135mj/cm2 to 540mj/cm2 with mean value 
of 293mj/cm2[96,97]
We started  with  the  initial  dose  of  70% of  the  MED and a  Baseline  Total 
Lesional  Severity Scale(TLSS) Scoring was calculated for  each patient.  The 
initial dose when compared to other studies varied from 0.03J/cm2 to 0.7J/cm2 
where MED values were not determined to initiate the treatment[91,92]. In our 
study , the treatment was given thrice weekly for five weeks (15 sittings) with 
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10%  increment  following  each  dose  and  the  TLSS  scoring  was  calculated 
before starting the treatment(Baseline) and at the end of five, ten and fifteen 
treatments  .  The  mean  TLSS  score  after  the  treatments  were  reduced  in 
NbPUVB when compared to NbUVB after 10 sessions and this value (p value = 
0.006)was statistically significant. However by the end of our study, after 15 
treatments there was no stastical  difference between NBUVB & NbPUVB(p 
value = 0.837).
In a similar study conducted by Sakuntabhai et al wherein the MED was not 
determined and the initial dose was 0.7J/cm2 and the increment was 40 % after 
each dose given at twice weekly intervals for all patients. They concluded that 
psoralen enhanced the therapeutic  efficacy when combined with NbUVB as 
compared to NbUVB alone[92] 
In another study conducted by Morrison WL et al comparing the therapeutic 
effects  of  broad  band  UVB  (FS-40  sunlamp  bulbs)  radiation  versus  UVB 
radiation plus methoxsalen in 10 cases of psoriasis, they concluded that there 
was no detectable difference in the response between UVB plus methoxsulen 
and UVB phototherapy alone[91].
Subsequently we are planning to measure the minimal phototoxic dose (MPD) 
to NbUVB following administration of oral psoralen.
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Conclusion:
We conclude that addition of psoralen does not increase the efficacy of 
Narrow Band UVB
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MASTER CHART
S.NO Name Age Sex MED Initial Dose Total Cumulative Dose
Number of 
Treatments
1 Vinayagam 37 Male 750mj 525mj 16588mj 15
2 Sundararajan 62 Male 500mj 350mj 11064 mj 15
3 Ariniyarajan 31 Male 500mj 350mj 11064 mj 15
4 Duraisamy 70 Male 300mj 210mj 7249 mj 15
5 Subramaniam 69 Male 950mj 660mj 20903 mj 15
6 Suresh Kumar 57 Male 500mj 350mj 11064 mj 15
7 Logaswaran 54 Male 250mj 175mj 5500 mj 15
8 Raja 34 Male 450mj 315mj 9888 mj 15
9 Subramanian 33 Male 300mj 210mj 7249 mj 15
10 Muthulakshmi 59 Female 400mj 280mj 10953 mj 15
11 Nirmala 46 Female 500mj 350mj 11064 mj 15
12 Kumaraguru 51 Male 350mj 245mj 7710 mj 15
13 Karthikeyan 35 Male 300mj 210mj 7249 mj 15
14 Rajamanickam 48 Male 350mj 245mj Lost for Follow-up 2
15 Yuvaraj 52 Male 300mj 210mj 974 mj 4
16 Palanisamy 25 Male 250mj 175mj 810 mj 4
17 Karupasamy 48 Male 350mj 245mj 2783 mj 8
